BioTime (BTX) 4.86 -0.07

BioTime, Inc.
(BTX) 4.86 -0.07

Last Trade:	4.11	Day Range:	4.11 - 4.19
Trade Time:	04:05PM	52wk Range:	3.35 - 6.35
Prev. Close:	4.18	Market Cap:	206.91M
Open:	4.14	Div Yield:	0
Volume:	45847	PE:
EPS:	-0.39

The Latest On BTX

BioTime and Subsidiary LifeMap Sciences Announce Agreement to Market MalaCards 5/22/12 8:45am

HyStem-C Demonstrated Effective when Formulated with Human Heart Cells and Transplanted in an Animal Model of Heart Disease 5/14/12 8:45am

BioTime's Subsidiary ReCyte Therapeutics, Inc. Provides Update on Preclinical Development of Vascular Progenitors for the Treatment of Age-Related Vascular Disease 4/23/12 2:33pm

BioTime and its Subsidiary OrthoCyte Corporation Provides Update on Preclinical Development of OTX-CP07 4/23/12 2:33pm

BioTime's Subsidiary Cell Cure Neurosciences Provides Update on OpRegen® Product Development 4/23/12 2:14pm

BioTime Provides Update on ReneviaTM Product Development; Product Development on Track for CE Marking by 2013 4/23/12 2:04pm

BioTime Demonstrates Efficient Method for the Manufacture of Cartilage-Producing Cells from Human Embryonic Stem Cells 4/23/12 9:15am

BioTime and Subsidiary LifeMap Sciences Announce Agreement to Acquire XenneX 4/20/12 8:46am

BioTime Board of Directors Forms Science and Tech Committee 4/12/12 9:12am

BioTime Licenses Technology for Key Regulatory Gene Underlying Cancer and Stem Cell Reprogramming 1/24/12 9:45am

BioTime to Produce Stem Cells for Research in Muscle Disorders 1/3/12 9:45am

BioTime Signs Agreement with USCN Life Science to Source Antibody-Based Products 12/21/11 9:45am

BioTime and Subsidiary LifeMap Sciences Announce Agreement to Market MalaCards 5/22/12

HyStem-C Demonstrated Effective when Formulated with Human Heart Cells and Transplanted in an Animal Model of Heart Disease 5/14/12

BioTime's Subsidiary ReCyte Therapeutics, Inc. Provides Update on Preclinical Development of Vascular Progenitors for the Treatment of Age-Related Vascular Disease 4/23/12

BioTime and its Subsidiary OrthoCyte Corporation Provides Update on Preclinical Development of OTX-CP07 4/23/12

BioTime's Subsidiary Cell Cure Neurosciences Provides Update on OpRegen® Product Development 4/23/12

BioTime Provides Update on ReneviaTM Product Development; Product Development on Track for CE Marking by 2013 4/23/12

BioTime Demonstrates Efficient Method for the Manufacture of Cartilage-Producing Cells from Human Embryonic Stem Cells 4/23/12

BioTime and Subsidiary LifeMap Sciences Announce Agreement to Acquire XenneX 4/20/12

BioTime Board of Directors Forms Science and Tech Committee 4/12/12

BioTime Licenses Technology for Key Regulatory Gene Underlying Cancer and Stem Cell Reprogramming 1/24/12

BioTime to Produce Stem Cells for Research in Muscle Disorders 1/3/12

BioTime Signs Agreement with USCN Life Science to Source Antibody-Based Products 12/21/11

Microcap Movers for Tuesday December 20, 2011 12/20/11

Calls Purchased on BioTime, Inc. (BTX) 4/11/11

Puts Purchased on BioTime, Inc. (BTX) 3/17/11

Puts Purchased on BioTime, Inc. (BTX) 3/7/11

BioLogic Equity Opens BTX With Sell 1/6/11

Trade BTX
NOW!

Partner Headlines

Nokia Corporation, Arch Coal Among Stocks falling to Annual Lows Friday 4/20/12

Press Releases

Global Botulinum Toxin Market to Reach US$4.3 Billion by 2018, According to New Report by Global Industry Analysts, Inc. 3/20/12 PRWeb

North American Facial Injectable Market to Grow to More Than $1.4 Billion by 2016 1/18/12 Business Wire

European Facial Injectable Market Will Rebound Strongly in 2013, Reaching Double-Digit Growth by 2016 12/19/11 Business Wire

Get the latest BTX stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for BioTime, Inc. stock price.

BioTime, Inc. by YCharts

BioTime (BTX) 4.86 -0.07

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On BTX

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social